PharmaCyte Biotech Inc (PMCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has a cash flow conversion efficiency ratio of -0.027x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-979.52K) by net assets ($36.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmaCyte Biotech Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how PharmaCyte Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PharmaCyte Biotech Inc (PMCB) financial obligations for a breakdown of total debt and financial obligations.
PharmaCyte Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaCyte Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Addex Therapeutics Ltd
SW:ADXN
|
-0.089x |
|
Sego Resources Inc
V:SGZ
|
-0.015x |
|
Industrial Minerals Ltd
AU:IND
|
-0.077x |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
-0.026x |
|
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc
LSE:ATR
|
0.000x |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
-0.055x |
|
SCC Holdings Bhd
KLSE:0158
|
0.099x |
|
Tri-Mode System M Bhd
KLSE:0199
|
0.023x |
Annual Cash Flow Conversion Efficiency for PharmaCyte Biotech Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of PharmaCyte Biotech Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see PMCB stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $51.89 Million | $-2.98 Million | -0.057x | -5.41% |
| 2024-04-30 | $39.51 Million | $-2.15 Million | -0.054x | -4.32% |
| 2023-04-30 | $72.69 Million | $-3.79 Million | -0.052x | -13.98% |
| 2022-04-30 | $89.92 Million | $-4.12 Million | -0.046x | +90.82% |
| 2021-04-30 | $6.68 Million | $-3.33 Million | -0.499x | -8.53% |
| 2020-04-30 | $5.09 Million | $-2.34 Million | -0.459x | +19.54% |
| 2019-04-30 | $5.04 Million | $-2.88 Million | -0.571x | +35.14% |
| 2018-04-30 | $5.77 Million | $-5.08 Million | -0.881x | -113.24% |
| 2017-04-30 | $8.09 Million | $-3.34 Million | -0.413x | +38.03% |
| 2016-04-30 | $6.52 Million | $-4.35 Million | -0.666x | +13.26% |
| 2015-04-30 | $5.94 Million | $-4.56 Million | -0.768x | -339.64% |
| 2014-04-30 | $8.94 Million | $-1.56 Million | -0.175x | -141.24% |
| 2013-04-30 | $-921.46K | $-390.43K | 0.424x | +272.55% |
| 2012-04-30 | $-2.28 Million | $-259.29K | 0.114x | +37.82% |
| 2011-04-30 | $-2.73 Million | $-225.23K | 0.083x | -83.47% |
| 2010-04-30 | $-1.95 Million | $-974.06K | 0.499x | +268.02% |
| 2009-04-30 | $3.99 Million | $-1.19 Million | -0.297x | -85.49% |
| 2008-04-30 | $7.44 Million | $-1.19 Million | -0.160x | -95.28% |
| 2007-04-30 | $4.29 Million | $-351.60K | -0.082x | +66.25% |
| 2006-04-30 | $4.41 Million | $-1.07 Million | -0.243x | -111.25% |
| 2005-04-30 | $-1.30 Million | $-2.80 Million | 2.160x | +49.95% |
| 2004-04-30 | $-153.43K | $-221.03K | 1.441x | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more